Unlocking Japan: Navigating Clinical Trials and Market Potential for Global Biopharma
As part of the “Developing Your New Medicine in Japan Faster” Endpoints Virtual Event, CMIC sponsored a panel discussion on Japan’s evolving clinical trial landscape and its potential for global pharma and biotech companies.
As the world’s third-largest pharmaceutical market, Japan offers a clinical development environment comparable to the US and Europe. Recent data shows Japan’s PMDA New Active Substance median approval time is faster than the US FDA, with clinical trial start-up times of around 5 months, similar to Australia, Korea and Taiwan.
Experts from leading clinical sites in Japan, global sponsors and CMIC Group shared insights and real-life examples of patient recruitment, site selection, clinical trial execution and regulatory navigation in Japan. Don’t miss this opportunity to learn how your company can successfully tap into the Japanese market and accelerate drug development – Download the free resource today
For the full “Developing Your New Medicine in Japan Faster” webinar, visit the Endpoints News website.
